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Ivermectin induces apoptosis of esophageal
squamous cell carcinoma via mitochondrial
pathway
Nana Xu1†, Mengmeng Lu1†, Jiaxin Wang1†, Yujia Li1, Xiaotian Yang1, Xiajie Wei1, Jiaoyang Si1, Jingru Han1,
Xiaojuan Yao1, Juanmei Zhang1, Junqi Liu2, Yanming Li3*, Hushan Yang4* and Dengke Bao1*

Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is the most predominant primary malignant tumor
among worldwide, especially in China. To date, the successful treatment remains a mainly clinical challenge, it is
imperative to develop successful therapeutic agents.
Methods: The anti-proliferative effect of ivermectin on ESCC is investigated in cell model and in nude mice model.
Cell apoptosis was assessed using flow cytometry, TUNEL assay and western blotting. Mitochondrial dysfunction was
determined by reactive oxygen species accumulation, mitochondrial membrane potential and ATP levels.
Results: Our results determined that ivermectin significantly inhibited the proliferation of ESCC cells in vitro and in
vivo. Furthermore, we found that ivermectin markedly mediated mitochondrial dysfunction and induced apoptosis
of ESCC cells, which indicated the anti-proliferative effect of ivermectin on ESCC cells was implicated in mitochondrial
apoptotic pathway. Mechanistically, ivermectin significantly triggered ROS accumulation and inhibited the activation
of NF-κB signaling pathway and increased the ratio of Bax/Bcl-2.
Conclusions: These finding indicated that ivermectin has significant anti-tumour potential for ESSC and may be a
potential therapeutic candidate against ESCC.
Keywords: ESCC, Ivermectin, Apoptosis, Mitochondrial, NF-κB
Background
Esophageal squamous cell carcinoma (ESCC) is one
of the most common and fatal malignancies in China
[1, 2], which is considered as an aggressive cancer due
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to its poor prognosis and high mortality rate with a
5-year survival rate of only about 20% [3–5]. Since most
patients diagnosed with ESCC were found to have locally
advanced or metastatic disease and thus are not candidates for radical surgical resection, these patients are
treated with radiotherapy and chemotherapy [6, 7]. However, few candidate drugs that have long-term benefits
for ESCC therapy and the resistance of ESCC cells to
chemotherapy, which suggests that it is urgent to identify
novel therapeutic alternatives or agents to improve systemic therapy for ESCC patients.
Ivermectin is a polycyclic lactone pesticide produced
by streptomyces avermitilis and is found to be a broadspectrum effect against parasites [8, 9]. Moreover, some
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studies had revealed the anti-proliferative potential of
ivermectin in colon cancer, ovarian cancer, melanoma
and leukemia by inducing cell apoptosis and cell cycle
arrest, activating necrosis pathways and suppressing
tumor initiation and malignant transformation [10–12].
Previous study demonstrated that the growth of breast
cancer cells can be inhibited by ivermectin by inducing autophagy [13]. Ivermectin can also inhibit the cells
growth of human ovarian cancer through blocking the
oncogenic kinase PAK1 [14]. However, the effect and
molecular mechanism of ivermectin on ESCC growth
has not been clearly determined.
Inhibiting proliferation and increasing the sensitivity of
cancer cells to undergo apoptosis are considered important properties in developing novel chemotherapeutic
agents [15]. Mitochondria are important mediators of
tumorigenesis and targeting mitochondrial-associated
apoptotic pathways is a potential therapeutic strategy for
cancer [16]. In this study, we first evaluated the anti-proliferative effect of ivermectin on ESCC cells in vitro and
in vivo. Our results shown that ivermectin inhibit ESCC
cells growth and induce ESCC cells apoptosis through
mitochondria-dependent ROS production. Further, we
demonstrate that ivermectin induced mitochondrial dysfunction and ROS accumulation of ESCC cells, which
subsequently inhibited the activation of NF-κB signaling
pathway and induced ESCC cells apoptosis. These findings demonstrated that ivermectin may be a potential
candidate drug for ESCC therapy.

Methods
Cell culture and treatment

Esophageal squamous carcinoma cell lines and Normal
esophageal epithelial cells, KYSE-70, KYSE-30 and NE-3
were purchased from Nanjing Kebai Biotechnology Co.,
ltd. The cells were cultured in RPMI-1640 (10040-CVR,
Corning) medium containing 10% fetal bovine serum
(04-001-1Acs, BI) in a 37°C 5% C
 O2 incubator, and cells
were grown to 65%-75% confluence and treated under
various conditions as indicated.
Cell viability, proliferation and lactate dehydrogenase
(LDH) leakage assays

ESCC cells and NE-3 were seeded in 96-well plates
(5×105 cells/well or 1×105 cells/well) for 24 h, and
treated with ivermectin (S1351, Selleck Chemicals) at
serially diluted concentrations of 2.5, 5, 10, 15, 20 μM on
NE-3 and KYSE-70, 2, 4, 6, 8, 10 μM on KYSE-30 for 48
h. We found that the half maximal-inhibitory concentration (IC50) of ivermectin for KYSE-70 and KYSE-30 cells
was close to 10 μM and 6 μM, respectively. Thus, 10 μM
and 6 μM ivermectin were used for further experiments
to evaluate the anti-proliferative effect on ESCC cells.
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MTT assay was performed to assess the viability of ESCC
as described previously [17]. ESCC cells were seeded at
a density of 2000 cells/well or 500 cells/well in 6-well
plates, incubated for 24 h, and then exposed to ivermectin for 10-14 days. Next, the medium was removed and
cells were fixed with 4% paraformaldehyde for 15 min,
washed three times with PBS and incubated with 0.5%
crystal violet solution (C8470, Soiarbio) for another 5
min. The colonies were counted and assays from three
independent experiments. EdU (C10310, Ribobio) incorporation assay were used to evaluate the proliferation of
cells according to the manufacturer’s instructions. Then
results were analyzed with a fluorescence microscope
(Olympus Corporation U-LH100HG). LDH leakage was
measured using a colorimetric LDH assay kit (C0017,
Beyotime) following the manufacturer’s recommended
protocol. For relative quantification, the value of absorbance in each group was normalized to the control group.
Cell cycle of ESCC cells after treatment with ivermectin
is analyzed using Cell cycle kit (C6031, US Everbright)
following manufacturer’s instructions and determined by
flow cytometry using CytoFLEX (Beckman Coulter).
Cell apoptosis assay

Cell apoptosis was assessed using the Annexin-V-FITC
apoptosis detection kit (C6031, US Everbright). ESCC
cells were seeded in 6-well plates for 24 h, and treated
with ivermectin at 5, 10, 15 μM on KYSE-70 and 4, 6,
8 μM on KYSE-30 for 48 h, the apoptosis was assessed
following the manufacturer’s protocol and analyzed by
a flow cytometry (FACSVerse, BD), and the data were
analyzed with Flowjo VX10 Software (VX10, USA). Cell
apoptosis was also detected by using the TUNEL assay
kit (T6013, UE) and Hoechst 33342 (H4047, UE) staining
following the manufacturer’s protocol. The cellular nuclei
were stained with the TUNEL reaction overnight at 4°C
and fixed with 4% paraformaldehyde for 5min. After
washing three times using PBS, the cells were incubated
with Hoechst 33342 for 10 min. The TUNEL-positive
cells (green) and Hoechst 33342 (blue) staining patterns
were detected by fluorescence microscope (Olympus
Corporation U-LH100HG).
Detection of reactive oxygen species, mitochondrial
membrane potential (MMP) and ATP production

The cells were planted in 6-well plates and cultured overnight, exposed to ivermectin at 37°C for 48 h. Cellular
reactive oxygen species (ROS) levels were detected by the
fluorescent probe DCFH-DA following the manufacturer’s protocols (S0033S, Beyotime) [18]. Briefly, ESCC cells
suspension were incubated with 10 μM DCFH-DA for
20min at 37°C and analyzed by a flow cytometry (FACSVerse, BD), and the data were analyzed with Flowjo VX10
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Software (VX10, USA). The alteration of cellular MMP
was evaluated using JC-1 kit (C2006, Beyotime). Cells
were adjusted to a density of 5 × 105/ml and stained
with 2 μg/ml JC-1 dye for 20 min at 37°C, the results
were observed by a fluorescence microscope (Olympus
Corporation U-LH100HG). The total ATP levels were
determined using the Cell Titer-Glo Luminescent assay
(FF2000, Promega) according to the manufacturer’s
instructions.
Subcutaneous xenograft models

5-week-old female Balb/c nude mice (Beijing Charles
River Laboratories, Beijing, China) were randomly
divided into indicated groups (n=5). 5 × 106 ESCC
cells in 20 μL serum free RPMI-1640 was injected into
the right flanks to establish the subcutaneous xenograft
nude mice model. Tumor size was measured every two
days, and the tumor volume was calculated according to
(Width2 × Length)/2. When the tumor volumes reached
100 mm3, mice were randomized into two groups receiving 0.1 mL of saline or 25 mg/kg ivermectin per nude
mice, respectively. The nude mice were monitored twice
a week for palpable tumor formation. Then, all mice
were euthanized by intravenous with 100 mg/kg sodium
pentobarbital (P3761, Sigma) and the tumors were harvested and weighted. All experiments in this study were
performed in accordance with relevant guidelines and
regulations and were approved by Ethics Committee
of Henan University. Animal experiments were carried
out in compliance with the ARRIVE guidelines and was
approved by the Institutional Animal Care and Use Committee of Henan University (HUSOM-2019-031).
qPCR, Western blot, IHC

Total RNA extraction, complementary DNA synthesis, and qPCR were performed as previously described
[19]. Primer sequences of qPCR were provided in Supplementary Table 2. Preparation of whole-cell protein
lysates and western blotting analysis were performed as
we described before [17, 20]. Primary antibodies used in
this study included anti-P65 (8242T; D14E12; Cell Signaling), anti-pP65 (3033T; 93H1; Cell Signaling), anti-IκBα
(4814T; L35A5; Cell Signaling), anti-pIκBα (2859T; 14D4;
Cell Signaling), anti-PARP-1 ( sc-56197; 194C1439; Santa
Cruz Biotechnology), anti-cleaved PARP-1 (sc-56196;
5A5; Santa Cruz Biotechnology), anti-Bcl-2 (12789-1-AP;
Polyclonal Antibody), anti-Bax(50599-2-lg; Polyclonal
Antibody), anti-Cleaved-caspase-3 (CY5031; Abways),
and anti-Cleaved-caspase-9 (CY5682; Abways). The IHC
staining (D601037, Sangon Biotech) was detected by
using immunohistochemistry kit according to the manufacturer’s instructions. The cleaved caspase 3 (CY5031;
Abways), ROS1 (ab189925; EPMGHR2; Abcam), p-p65
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(3033T; Cell Signaling) and Ki-67 (CY5542; Abways)-positive staining was detected using a microscope (Nikon,
E100) and quantification using the ImageJ software (NIH,
Bethesda, MD, USA). Details of reagents used in this
study were provided in Supplementary Table 1.
Statistical treatment

The results were expressed as the mean ± SD. Mean values were calculated from data obtain from experiments
performed in triplicate. The differences between the
experimental and control groups were compared using
one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical software SPSS20.0 was used
in data processing and for analyzing the significance
between groups with the t-test. p < 0.05 was considered
statistically significant.

Results
Ivermectin inhibits proliferation of ESCC cells in vitro

To investigate the anti-proliferative effect of ivermectin
on ESCC cells, the MTT assay was conducted to assess
the growth of ESCC cells after incubated with ivermectin for 48h. As shown in Fig. 1A, ivermectin markedly
decreased the cell viability of ESCC cells with a dosedependent manner. Moreover, the half maximal-inhibitory concentration (IC50) of ivermectin for KYSE-70 and
KYSE-30 cells was close to 10 μM and 6 μM, respectively.
We also found that the typical morphological characteristic of ESCC cells was changed after ivermectin treatment
for 48h. The morphology of ESCC cells with ivermectin
treatment became irregular, wrinkled or even broken and
smaller and roundness than the control group (Fig. 1B).
Lower concentrations of ivermectin (2.5-15 μM) had
no cytotoxic effect in NE-3 cells, while 20 μM ivermectin slightly inhibited viability of NE-3 cells viability
(Fig. 1A). We next performed another cytotoxicity evaluation in ESCC cells after ivermectin treatment using the
LDH cytotoxicity assay kit after ivermectin treatment.
As shown in Fig. 1C, treatment with ivermectin significantly increased LDH release in the medium, which was
consistent with MTT assay. The anti-proliferative effect
of ivermectin on ESCC cells was determined by colony
formation and EdU incorporation assays. As shown in
Fig. 1D, the proliferative potential and colony formation
ability of ESCC cells were remarkably suppressed after
ivermectin treatment. EdU incorporation was remarkably reduced in ivermectin-treated ESCC cells compared
to controls (Fig. 1E). Cell cycle analysis performed using
flow cytometry indicated that ivermectin significantly
decrease the population of cells in S and G2/M phase
and increase the population of G1 with a concentrationdependent manner (Fig. 1F). Collectively, these results
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Fig. 1 Ivermectin inhibits proliferation of ESCC cells in vitro. A. Viability of cells was assessed by MTT assay. B. The morphological changes of ESCC
cells were observed by phase contrast microscopy at 200× magnification, Scale bar = 50 μm; The anti-proliferative effect of ivermectin on ESCC
cells was determined by LDH assay (C); colony formation (D), Scale bar = 10 mm; and EdU incorporation assays (E), Scale bar = 50 μm; F. Cell cycle
of ESCC cells after treatment with was performed by flow cytometry. Values represent mean ± S.E.M. of 3 independent experiments. *P < 0.05, **P <
0.01; ***P < 0.001.

demonstrate that ivermectin inhibits the proliferation of
ESCC cells in vitro.
Ivermectin promotes apoptosis of ESCC cells

Apoptosis is a major form of cell death for cancer
cells induced by chemotherapeutic agents and implicated in the cytotoxic mechanisms of various classes
of chemotherapy [21]. Therefore, we first simultaneously evaluated the expression level of Bax and Bcl-2,
two apoptosis related proteins, and analyzed the ratio
of Bax/Bcl-2, simultaneously. As shown in Fig. 2A and
B, the expression level of pro-apoptotic factor Bax was
significantly increased after ivermectin treatment, while
the expression of anti-apoptotic factor Bcl-2 was markedly decreased when compared with control group. Thus,
the ratio of Bax/Bcl-2 was significantly increased in ivermectin-treated ESCC cells. The activation of the caspase
cascade is well known intrinsic cell apoptotic pathway
via mitochondria. The expression levels of cleaved-caspase-9, cleaved-caspase-3 and caspase downstream effectors (PARP) were estimated by western blot analysis. As
shown in Fig. 2C, after ivermectin treatment, the levels of

cleaved-caspase 9, cleaved-caspase 3 and cleaved-PARP
protein were remarkably increased. We further detected
whether ivermectin induced apoptosis in the ESCC cells
by Hoechst 33342 staining assays and flow cytometry
analysis using Annexin V-FITC/PI kit. Hoechst 33342
staining assays showed that the nuclear morphology of
ESCC cells exposure to ivermectin were condensed, fragmented and crescent shaped, while the control cells had
a round, bright and regular morphology (Fig. 2D). Using
TUNEL and Annexin-V FITC/PI assays by flow cytometry, we showed that the percentage of apoptotic ESCC
cells was significantly increased in the ivermectin group
compared to control (Fig. 2E and F). Taken together,
these data suggested that the inhibitory effect of ivermectin on ESCC cells was associated with cell apoptosis.
Ivermectin mediates mitochondrial dysfunction of ESCC
cells

Intracellular ROS, which are predominantly derived
from the mitochondria, are known to induce oxidative
damage and ultimately trigger a series of mitochondrial
associated events, including apoptosis. Consistent with
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Fig. 2 Ivermectin promotes apoptosis of ESCC cells. Western blotting (A) and qRT-PCR (B) analysis for the expression levels of Bax and Bcl-2 after
ivermectin treatment; C. The expression of caspase cascade (cleaved-caspase 9, cleaved-caspase 3, PARP, cleaved PARP) were analyzed by western
blotting; D. Cells were observed by fluorescence microscopy after staining with Hoechst 33342, Scale bar = 100 μm; E. Ivermectin-induced ESCC
cells apoptosis was determined by TUNEL assay (200×), Scale bar = 50 μm; F. Ivermectin-induced ESCC cells apoptosis was determined by PI/
Annexin-V assay using flow cytometry. *P < 0.05, **P < 0.01; ***P < 0.001.
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Fig. 3 Ivermectin mediates mitochondrial dysfunction of ESCC cells. A. Intracellular ROS levels were investigated by DCFH-DA fluorescence in ESCC
cells treatment with indicated; B. The expression levels of Bax and Bcl-2 were determined by western blot analysis; C. The expression of caspase
cascade (cleaved-caspase 9, cleaved-caspase 3, PARP, cleaved PARP) were analyzed by western blotting; D. Mitochondrial membrane potential was
observed by fluorescence microscope at 200 × magnifications, Scale bar = 50 μm; E. ATP production of ESCC cells after treated with ivermectin was
detected; F. The mitochondrial DNA copy number in ESCC cells treatment with invermectin was evaluated using qRT-PCR. *P < 0.05, **P < 0.01.

previous research, we found that ivermectin induced
intracellular ROS accumulation in ESCC cells [12].
To determine whether the ROS accumulation was
functionally important for ivermectin-induced apoptosis, we added the free radical scavenger N-acetylL-cysteine (NAC) to ivermectin-treated cells. NAC
markedly eliminated intracellular ROS induced by ivermectin (Fig. 3A) and abrogated ivermectin-induced the
increase of Bax/Bcl-2 ratio (Fig. 3B). Consistent with
this data, the expression of cleaved caspase 9, cleaved
caspase 3 and cleaved PARP proteins in ESCC cells
were significantly decreased after exposure to ivermectin and NAC, when compared with ivermectin alone
(Fig. 3C).

It had been demonstrated that mitochondriadependent apoptotic pathway play a vital role in
drug-induced apoptosis [22]. To determine whether
ivermectin induced ESCC cells apoptosis though a
mitochondria-dependent pathway, we examined the
mitochondrial function by mitochondrial membrane
potential, mitochondrial DNA contents change and
ATP production. As shown in Fig. 3D, we found that
more ESCC cells with green or orange fluorescence,
which indicated that mitochondrial membrane potential was decreased after ivermectin treatment. Ivermectin significantly decreased ATP production in
ESCC cells with a time-dependent manner (Fig. 3E).
To further verify the hypothesis, the mitochondrial
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DNA contents change in ESCC cells were detected
after ivermectin treatment. Simultaneity, our results
indicated that mitochondrial DNA contents were
significantly reduced in ESCC cells treatment with
ivermectin (Fig. 3F). These results indicated that ivermectin-induced ESCC cells apoptosis was associated
with mitochondrial dysfunction.

study, eliminating intracellular ROS by NAC markedly
abrogated ivermectin-induced inactivation of NF-κB
pathway, observed through the increased phosphorylation of IκBα and NF-κB p65 protein (Fig. 4C and D).
Taken together, these results indicated that ivermectin induces apoptosis of ESCC cells through NF-κB
pathway.

Ivermectin induces apoptosis of ESCC cells through NF‑κB
pathway

Ivermectin suppressed xenograft growth of ESCC cells
in vivo

The NF-κB signaling pathway is involved in ESCC carcinogenesis and progression and is hyperactivated
in ESCC cells and promotes cell survival. To evaluate whether NF-κB signaling pathway was implicated
in ivermectin-mediated anti-tumor properties of
ESCC, the expression of related signaling molecules
in NF-κB pathway were measured. We observed that
ivermectin significantly decreased the phosphorylation and nuclear translocation of NF-κB p65 protein
in a concentration-dependent manner (Fig. 4A and B).
Subsequently, we also found that the phosphorylation
of IκBα, an upstream regulatory molecule of NF-κB
pathway, was inhibited in ESCC cells after ivermectin
treatment (Fig. 4A and B). Consistent with previous

To evaluate the anti-proliferative effects of ivermectin on
ESCC growth in vivo, xenograft nude mice model was
established by subcutaneously injecting ESCC cells. We
observed that the growth potential of ESCC cells-derived
subcutaneous tumor was remarkably attenuated by treatment with ivermectin. The size of xenografts tumor
treated with ivermectin was significantly smaller than
control saline groups (Fig. 5A) and the proliferation rate in
ivermectin treatment group was slower (Fig. 5B). Tumor
weight was also markedly reduced in ivermectin-treated
mice when compared to control group (Fig. 5C). Furthermore, the percentage of Ki67-positive cells in xenografts
tumor by injection of ivermectin was also notably attenuated (Fig. 5D and E). The p-p65 expression in nuclear was

Fig. 4 Ivermectin induces apoptosis of ESCC cells through NF-κB pathway. A and C. Western blotting analysis for the expression levels of p65,
p-p65, p-IκBα and IκBα in ESCC cells after ivermectin treatment; B and D. Quantified for the protein expression levels of (A) and (C). *P < 0.05, **P <
0.01; ***P < 0.001.
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Fig. 5 Ivermectin suppressed xenograft growth of ESCC cells in vivo. A, B and C. Tumor growth curves and weight of subcutaneous xenograft
tumor model developed from ESCC cells treatment with ivermectin as indicated (n=5); D and E. Representative immunohistochemistry images of
Ki67, ROS1, p-p65 and cleaved-caspase 3 in xenograft tumor developed from KYSE-70 and KYSE-30 cells treatment with ivermectin as indicated.
Scale bar: 300μm. *P < 0.05, **P < 0.01; ***P < 0.001.
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significantly decreased in xenografts tumor cells by injection of ivermectin (Fig. 5D and E). However, the expression of ROS1 and cleaved caspase 3 were remarkable
increased in ivermectin treatment group (Fig. 5D and E).
Taken together, these data suggest that ivermectin inhibited the growth of ESCC cells both in vivo.

Discussion
In this study, the anti-proliferative potential of ivermectin
on ESCC cells was evaluated. Our results demonstrated
that ivermectin could inhibit the proliferation of ESCC
cells in vivo and in vitro. Furthermore, we found that
ivermectin induced apoptosis of ESCC cells, which was
implicated with mitochondrial pathway. In addition, the
apoptosis induced by ivermectin triggered by mitochondrial dysfunction-derived ROS through NF-κB signaling
pathway (Fig. 6).
Recent studies demonstrated that antiparasitic drugs
can inhibit the growth of multiple cancers, such as melanoma, ovarian cancer, breast cancer, glioblastoma [11,
13, 23, 24]. Here, we found that treatment with ivermectin conspicuously suppressed the proliferation of
ESCC cells by MTT, colony formation and EdU incorporation assay and were demonstrated in vivo of xenografts tumor. All control xenografts displayed stronger
Ki67 staining than that of ivermectin-treated mice.
Taken together, these data suggest that ivermectin
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inhibits the growth of esophageal cancer both in vitro
and in vivo. It had been reported that ivermectin inhibited breast and ovarian cancer cells proliferation by
promoting PAK1 ubiquitination degradation and cytostatic autophagy by suppressing Akt/mTOR signaling
pathway [13, 14]. The anti-proliferative effect of ivermectin on glioma cells was implicated with ivermectinindcued cell cycle arrest and apoptosis [23]. Here, our
results on ESCC cells indicated that the anti-proliferative effect of ivermectin on ESCC was significantly
mediated via apoptosis. We found that treatment with
ivermectin significantly increased nuclei fragmentation, apoptosis and G1 cycle arrest in ESCC cells.
NF-κB signaling pathway has obvious functions of
inhibiting apoptosis, promoting cell proliferation and
immune activation, and is also closely related to the differentiation, invasion and migration of several tumor
cells [25]. Previous study had demonstrated that NF-κB
activation promoted transcription of Bcl-2, VEGF, MMP
and inhibited Bax expression, which reduced apoptosis and contributed to angiogenesis and progression of
ESCC [26]. Blocking of NF-κB signaling pathway significantly suppressed ESCC cells growth, prevented angiogenesis and metastasis of ESCC, and sensitized ESCC
to chemotherapeutic drugs [27, 28]. We also found that
NF-κB pathway was markedly suppressed after treatment with ivermectin. Consistent with previous research,

Fig. 6 Schematic depicting the anti-proliferative potential of ivermectin on ESCC cells.
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our results indicated ivermectin inhibited the growth of
ESCC cells by regulating the NF-κB signaling pathwaymediated apoptosis, at least in part, mediated by regulation of Bax and Bcl-2 expression. The above results show
that ivermectin, as an external stimulus signal, blocks further activation of the NF-κB signaling pathway, thereby
attenuating the anti-apoptotic effect, and the downstream
apoptotic signal further promotes apoptosis.
Mitochondrion is the central of cytosolic signaling
transduction and plays a vital role in apoptotic pathway
and is implicated in several anticancer drugs [22, 29, 30].
Recently research determined that ivermectin suppresses
tumour growth and metastasis through degradation of
PAK1 in ESCC [31]. However, how the mitochondria
is involved in ivermectin-induced apoptosis remains
unclear. Here, we determined mitochondrial dysfunction in ESCC cells treated with ivermectin, seen in the
reduced mitochondrial DNA contents, decreased mitochondrial membrane potential and inhibited ATP production. Ivermectin markedly increased ROS levels of
ESCC cells and scavenging the ROS by NAC surprisingly
blocked the apoptosis and NF-κB inactivation, suggesting that ROS-mediated apoptosis was the main mechanism for ivermectin activity, while other pathways may
also play a role to be explored in the future. The results
indicated that mitochondrial dysfunction-derived ROS
maybe trigger NF-κB signaling pathway and induce apoptosis by ivermectin treatment.

Conclusions
We demonstrated that ivermectin effectively inhibit the
proliferation of ESCC cells by inducing mitochondrial
dysfunction, suppressing NF-κB signaling and promoting
apoptosis. Our results suggest that ivermectin may be a
potential therapeutic target against ESCC.
Abbreviations
ESCC: Esophageal squamous cell carcinoma; LDH: Proliferation and lactate
dehydrogenase; EdU: Ethynyl deoxyuridine; MMP: Mitochondrial membrane
potentialCellular; ROS: Reactive oxygen species; IC50: The half maximal-inhibitory concentration; NAC: Free radical scavenger N-acetyl-L-cysteine.
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